Brexpiprazole Tablets Generics - Manufacturers & Suppliers
Rexulti®(US & EU)
| Product/Composition:- | Brexpiprazole Tablets |
|---|---|
| Strength:- | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg |
| Form:- | Tablets |
| Reference Brands:- | Rexulti®(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Brexpiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. This balanced activity helps modulate dopamine and serotonin pathways in the brain. It is used for the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder (MDD) in adults, offering improved mood stabilization and reduced psychotic symptoms with a lower risk of extrapyramidal side effects.
Brexpiprazole tablets are FDA-approved in the United States for the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder (MDD) in adults. In the European Union, Brexpiprazole is approved under brand names like Rxulti, primarily for schizophrenia, following centralized EMA procedures. Regulatory compliance includes GMP standards, comprehensive clinical data, and documentation on metabolic side effects, akathisia, and suicidality risks. U.S. submissions must meet FDA requirements including boxed warnings for elderly dementia-related psychosis. EMA approval mandates a full Risk Management Plan (RMP) and pharmacovigilance commitments. For dossier-ready Brexpiprazole tablets and sourcing options, visit Pharmatradz.com — your trusted B2B pharma platform.